SCHEMBL12044230

SCHEMBL12044230

O=C(Nc1cccc2ccccc12)c1ccc(OC(=O)C2CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.64
▸ RAB9A P51151 4/20 0.64
▸ NPC1 O15118 4/20 0.64
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ GRIN2D O15399 1/20 0.58
▸ GRIN2C Q14957 1/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ LMNA P02545 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ MAPT P10636 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ ELANE P08246 2/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ POLB P06746 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29124110 0.79 NPC1 (1.00) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12043937 0.79 KMT2A (0.70) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12043936 0.78 KMT2A (0.65) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12043940 0.78 KMT2A (0.68) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12043941 0.77 KMT2A (0.67) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12044225 0.77 KMT2A (0.67) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL26885232 0.76 NPC1 (0.81) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL30184438 0.76 NPC1 (1.00) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL4642544 0.76 NPC1 (1.00) KMT2ARAB9ANPC1CYP1A2CYP3A4
SCHEMBL12043935 0.76 GRIN2D (0.79) KMT2ARAB9ANPC1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319416-A1 Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2011-12-29 — — US disclosed
US-20110319416-A1 Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2011-12-29 — — US disclosed
WO-2010088408-A2 SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319416-A1 Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B KMT2A 1870/4885RAB9A 742/4885NPC1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback